Nath Bio-Genes (India) Limited (NATHBIOGEN) Financial Results — Revenue ₹4,316 Cr

Revenue: ₹4,316 CrNet Profit: ₹384 Cr

📢 Key Event
Nath Bio-Genes reported FY26 revenue of ₹4,316 million, up 19% YoY, with PAT at ₹384 million and EPS of ₹23.42.

🔄 What Changed
PAT declined due to higher finance and marketing costs despite 19% revenue growth; effective tax rate rose to 11%; international revenue target set at 10-15% (INR 150 crores on INR 1,000 crore top line); FY27 revenue growth guided at 15-20%; cotton volume growth of 22% YoY and realization improvement from ₹275 to ₹293.

🔮 What's Next
FY27 revenue growth of 15-20%; international revenue to reach 10-15% of total; cotton volume growth expected to continue; inventory management strategy to support future production stability.

💡 Investor Takeaway
Shareholders should note PAT pressure from rising costs and taxes, but long-term growth is supported by cotton volume gains, international expansion, and portfolio diversification.

Nath Bio-Genes reported FY26 revenue of ₹4,316 million, up 19% YoY, with PAT at ₹384 million and EPS of [amount context mismatch]. EBITDA reached [amount context mismatch] million (12% margin), while gross margin held at 56%. International revenue is targeted at 10-15% of total, contributing INR 150 crores against a projected INR 1,000 crore top line. FY27 revenue growth is expected at 15-20%, driven by 22% cotton volume growth and expansion in paddy and maize. Management highlighted inventory adjustments affecting cash flow and a rising effective tax rate of 11% due to marketing expenses.

📄 View Original Announcement (PDF)

📊 Stock Analysis — NATHBIOGEN ✨ Ask AI About This